ProShares UltraShort NASDAQ Biotechnology
7 hedge funds and large institutions have $1.88M invested in ProShares UltraShort NASDAQ Biotechnology in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
173% more capital invested
Capital invested by funds: $691K → $1.88M (+$1.19M)
40% more funds holding
Funds holding: 5 → 7 (+2)
4.86% more ownership
Funds ownership: 4.91% → 9.77% (+4.9%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$484K |
| 2 |
IMC Chicago
Chicago,
Illinois
|
+$477K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$267K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$12.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$118K |
| 2 |
Morgan Stanley
New York
|
-$5.05K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OMC
1
Old Mission Capital
Chicago,
Illinois
| $776K | +$484K | +9,474 | +143% |
|
|
2
IMC Chicago
Chicago,
Illinois
| $450K | +$477K | +9,334 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $366K | -$118K | -2,303 | -23% |
|
|
4
Citadel Advisors
Miami,
Florida
| $252K | +$267K | +5,236 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $33K | +$12.4K | +243 | +55% |
|
|
6
Morgan Stanley
New York
| $4K | -$5.05K | -99 | -52% |
|
7
Citigroup
New York
| $2K | – | – | – |
|
BIS Hedge Fund Activity: Q1 2022 in Review
7 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2022, worth a combined $1.88M — up 173% from $691K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BIS positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Old Mission Capital, adding an estimated $484K. The largest seller was Tower Research Capital (TRC), cutting an estimated $118K.
- 7 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2022, up from 5 in Q4 2021.
- Funds reported $1.88M of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2022, up 173% quarter-over-quarter.
- 2 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2022 and 0 closed out, a net change of +2 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2022 was Old Mission Capital, an estimated $484K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q1 2022 was Tower Research Capital (TRC), an estimated $118K sold.
Based on aggregated 13F filings for Q1 2022.